Beam Therapeutics Full Year 2024 Earnings: Beats Expectations
Full Year 2024 Results Key Financial Results Revenue: US$63.5m (down 83% from ...
Beam Therapeutics (BEAM) Gets a Hold from Barclays
In a report released today, Gena Wang from Barclays maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target ...
Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock So Far in 2025
We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...
ETF Daily News3d
Beam Therapeutics (BEAM) to Release Earnings on Tuesday
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, February 25th.Analysts expect Beam Therapeutics to ...
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial ofBEAM-101; Dosing of 30 Patients and Updated Data Expected by ...
FiercePharma5d
Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
Channel NewsAsia Singapore15h
Business Blueprint: Making a Difference With Proton Beam Therapy
In collaboration with Hitachi, the National Cancer Centre Singapore has introduced Proton Beam Therapy - a treatment designed to target tumours with precision while reducing the impact on healthy ...
Beam Therapeutics sees cash runway into 2027
Beam expects that its cash, cash equivalents and marketable securities as of December 31, 2024, will enable the company to fund its anticipated ...